<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hematologic stem cell rescue after high-dose cytotoxic therapy is extensively used for the treatment of many hematopoietic and solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Gene marking studies suggest that occult <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells within the autograft may contribute to clinical relapse </plain></SENT>
<SENT sid="2" pm="."><plain>To date purging of autografts contaminated with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells has been unsuccessful </plain></SENT>
<SENT sid="3" pm="."><plain>The selective oncolytic property of reovirus against myriad malignant histologies in in vitro, in vivo, and ex vivo systems has been previously demonstrated </plain></SENT>
<SENT sid="4" pm="."><plain>In the present study we have shown that reovirus can successfully purge <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells within autografts </plain></SENT>
<SENT sid="5" pm="."><plain>Human monocytic and <z:mp ids='MP_0009440'>myeloma</z:mp> cell lines as well as enriched ex vivo <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:mp ids='MP_0009440'>myeloma</z:mp>, and <z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">Waldenström macroglobulinemia</z:e> patient <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specimens were used in an experimental purging model </plain></SENT>
<SENT sid="6" pm="."><plain>Viability of the cell lines or purified ex vivo <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, <z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">Waldenström macroglobulinemia</z:e>, and small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was significantly reduced after reovirus treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Further, <z:chebi fb="0" ids="37983">[35S]</z:chebi>-methionine labeling and <z:chebi fb="0" ids="8984">sodium dodecyl sulfate</z:chebi>-<z:chebi fb="0" ids="53656">polyacrylamide</z:chebi> gel electrophoresis (<z:chebi fb="26" ids="8984">SDS</z:chebi>-PAGE) of cellular proteins demonstrated reovirus protein synthesis and disruption of host cell protein synthesis as early as 24 hours </plain></SENT>
<SENT sid="8" pm="."><plain>Admixtures of apheresis product with the abovementioned <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells and cell lines treated with reovirus showed complete purging of disease </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, reovirus purging of enriched ex vivo <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was incomplete </plain></SENT>
<SENT sid="10" pm="."><plain>The oncolytic action of reovirus did not affect CD34+ stem cells or their long-term colony-forming assays even after granulocyte colony-stimulating factor (G-CSF) stimulation </plain></SENT>
<SENT sid="11" pm="."><plain>Our results indicate the ex vivo use of an unattenuated oncolytic virus as an attractive purging strategy for autologous stem cell transplantations </plain></SENT>
</text></document>